Quantcast

Latest Prostate Stories

2014-05-27 08:27:46

-- High calibre German consulting company appointed to assist CE Mark registration process SYDNEY, May 27, 2014 /PRNewswire/ -- Australian biotechnology company Minomic International Limited will register its MiStat(TM) ELISA prostate cancer test for CE Mark approval in the latter part of 2014. Achieving CE approval will be a key commercial milestone for the company, allowing it to sell and market its early detection diagnostic technology in the 33 member countries within the...

2014-05-20 16:27:05

New Analysis Suggests Oncotype DX Predicts Recurrence Risk After Prostatectomy Regardless of Post-Surgery Treatment REDWOOD CITY, Calif., May 20, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today presented positive results reinforcing the robustness of the Oncotype DX(®) prostate cancer test's development as a predictor of prostate cancer aggressiveness. A sub-analysis of a large Oncotype DX Genomic Prostate Score (GPS) development study, presented at the American...

2014-05-20 16:26:25

Two Studies Presented at 2014 AUA Annual Meeting SAN DIEGO, May 20, 2014 /PRNewswire/ -- GenomeDx Biosciences today announced the presentation of data showing that its Decipher® Prostate Cancer Classifier, a genomic test capable of predicting metastatic prostate cancer, was able to identify patients that may be spared of radiation therapy after prostate surgery who would have been otherwise classified as high risk based on current clinical practice guidelines. In a separate study,...

2014-05-20 08:34:18

New studies highlight impact of certain conditions on prostate cancer severity, role diet may play in etiology ORLANDO, Fla., May 20, 2014 /PRNewswire-USNewswire/ -- Three new studies featuring the impact of dietary and lifestyle factors on prostate cancer will be presented during the 109(th) Annual Scientific Meeting of the American Urological Association (AUA). The research will be highlighted by study authors during a special press conference at the Orange County Convention Center...

2014-05-18 12:20:20

ORLANDO, Fla., May 18, 2014 /PRNewswire-USNewswire/ -- With an accuracy rating of 98 percent, specially-trained dogs were able to smell volatile organic compounds (VOCs) released into urine by prostate tumors, setting the stage for a potentially new means of early prostate cancer detection, according to a new study at the 109(th) Annual Scientific Meeting of the American Urological Association (AUA). The study will be presented to the media during a special press conference on Sunday, May 18...

2014-05-17 12:20:17

Panel discusses long-term effect on quality of life ORLANDO, Fla., May 17, 2014 /PRNewswire-USNewswire/ -- A series of studies evaluating the outcomes, benefits, concerns and quality of life of men undergoing active surveillance for prostate cancer will be presented to media at a special press conference during the 2014 Annual Scientific Meeting of the American Urological Association (AUA). Stacy Loeb, MD, assistant professor at New York University, New York, NY, will moderate the session,...

2014-05-16 16:24:58

Oncotype DX® Prostate Cancer Test Enables More Precise Risk Assessment and Significantly Increases Number of Low-Risk Patients Who Can Confidently Choose Active Surveillance REDWOOD CITY, Calif., May 16, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) announced today that groundbreaking results from three studies of the Oncotype DX(®) prostate cancer test were published in European Urology. The peer-reviewed publication highlights studies that focus on addressing the need...

2014-05-16 08:26:14

SAN DIEGO, May 16, 2014 /PRNewswire/ -- GenomeDx Biosciences today announced the launch of the Decipher® Portal Professional, a mobile app designed for iPad tablets that allows registered medical practitioners to use and understand genomic information about prostate cancer and how it can impact their clinical practice. It offers physicians the opportunity to explore Decipher clinical data on interactive graphs, engage in hands-on exploration of clinical use scenarios and learn more...

2014-05-14 08:26:33

NEW YORK, May 14, 2014 /PRNewswire/ -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) specializes in the research and development of therapeutics and diagnostics, with a particular emphasis on products targeted for the unmet needs of the aging population. The Company has just completed its second Phase 3 clinical trial for its new drug for benign prostatic hyperplasia (BPH). Nymox has a number of drugs in development for other indications such as E. coli infection, Alzheimer's...

2014-05-08 08:32:48

SAN DIEGO, May 8, 2014 /PRNewswire/ -- GenomeDx Biosciences announced today that the company's Decipher® Prostate Cancer Classifier will be featured in multiple sessions during the American Urological Association (AUA) Annual Meeting taking place May 16-21 in Orlando, FL. Two data presentations will detail validation studies supporting the use of Decipher to predict risk of metastasis in men following prostate surgery. Decipher has also been included in independent CME and educational...


Latest Prostate Reference Libraries

Prostate
2013-03-04 15:21:55

The male prostate gland acts as an exocrine gland in the male reproductive system. It is a firm, partly muscular, chestnut sized gland near the neck of the urethra in males. Formation and Orientation The prostate is usually formed within the ninth week of the embryonic stage in reproductive development. The prostate can be separated into either “lobes” or “zones”. When looking at a prostate divided into zones, there are four distinct regions. The first zone is the Peripheral...

More Articles (1 articles) »
Word of the Day
grass-comber
  • A landsman who is making his first voyage at sea; a novice who enters naval service from rural life.
According to the OED, a grass-comber is also 'a sailor's term for one who has been a farm-labourer.'